BML-190 (IMMA) is a selectivecannabinoid CB2 receptorinverse agonist withKiof 435 nM, with 50-fold selectivity over CB1 receptor. In vitro
BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, BML-190 potentiates the forskolin-stimulated accumulation of cAMP. BML-190 reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of BML-190 decreases inositol phosphates accumulation by 38%. BML-190 is an aminoalkylindole. BML-190 is found to yield at least 15 metabolic products. BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction.
In vivo
Cell Data
cell lines:
Concentrations:0 μM -100 μM
Incubation Time:20 hours–24 hours
Powder Purity:≥99%
사양
동의어
IMMA | Ethanone, 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-(4-morpholinyl)-
사양 및 순도
10mM in DMSO
생화학 및 생리적 메커니즘
BML-190 (IMMA) is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.